The stock of Eton Pharmaceuticals Inc (ETON) has gone up by 22.26% for the week, with a 25.97% rise in the past month and a 164.34% rise in the past quarter. The volatility ratio for the week is 8.91%, and the volatility levels for the past 30 days are 5.87% for ETON. The simple moving average for the past 20 days is 22.46% for ETON’s stock, with a 128.21% simple moving average for the past 200 days.
Is It Worth Investing in Eton Pharmaceuticals Inc (NASDAQ: ETON) Right Now?
The 36-month beta value for ETON is at 1.26. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ETON is 24.46M, and currently, shorts hold a 0.78% of that float. The average trading volume for ETON on November 14, 2024 was 160.26K shares.
ETON) stock’s latest price update
Eton Pharmaceuticals Inc (NASDAQ: ETON)’s stock price has gone rise by 15.59 in comparison to its previous close of 9.17, however, the company has experienced a 22.26% increase in its stock price over the last five trading days. seekingalpha.com reported 2024-11-12 that Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants David Krempa – Chief Business Officer Sean Brynjelsen – Chief Executive Officer James Gruber – Chief Financial Officer Conference Call Participants Chase Knickerbocker – Craig-Hallum Operator Good afternoon, and welcome to the Eton Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode.
Analysts’ Opinion of ETON
Many brokerage firms have already submitted their reports for ETON stocks, with H.C. Wainwright repeating the rating for ETON by listing it as a “Buy.” The predicted price for ETON in the upcoming period, according to H.C. Wainwright is $9 based on the research report published on September 04, 2024 of the current year 2024.
Craig Hallum, on the other hand, stated in their research note that they expect to see ETON reach a price target of $8. The rating they have provided for ETON stocks is “Buy” according to the report published on May 06th, 2024.
B. Riley Securities gave a rating of “Buy” to ETON, setting the target price at $10 in the report published on October 14th of the previous year.
ETON Trading at 47.85% from the 50-Day Moving Average
After a stumble in the market that brought ETON to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 7.29% of gains for the given period.
Volatility was left at 5.87%, however, over the last 30 days, the volatility rate increased by 8.91%, as shares surge +28.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +129.93% upper at present.
During the last 5 trading sessions, ETON rose by +22.26%, which changed the moving average for the period of 200-days by +123.63% in comparison to the 20-day moving average, which settled at $8.66. In addition, Eton Pharmaceuticals Inc saw 142.01% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ETON starting from Opaleye Management Inc., who purchase 10,000 shares at the price of $7.98 back on Oct 23 ’24. After this action, Opaleye Management Inc. now owns 2,770,000 shares of Eton Pharmaceuticals Inc, valued at $79,814 using the latest closing price.
Opaleye Management Inc., the 10% Owner of Eton Pharmaceuticals Inc, purchase 33,970 shares at $7.03 during a trade that took place back on Oct 08 ’24, which means that Opaleye Management Inc. is holding 2,760,000 shares at $238,782 based on the most recent closing price.
Stock Fundamentals for ETON
Current profitability levels for the company are sitting at:
- -0.15 for the present operating margin
- 0.59 for the gross margin
The net margin for Eton Pharmaceuticals Inc stands at -0.16. The total capital return value is set at -0.32. Equity return is now at value -33.35, with -16.27 for asset returns.
Based on Eton Pharmaceuticals Inc (ETON), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 16.83. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -18.84.
Currently, EBITDA for the company is -0.29 million with net debt to EBITDA at 4.55. When we switch over and look at the enterprise to sales, we see a ratio of 7.32. The receivables turnover for the company is 6.2for trailing twelve months and the total asset turnover is 0.97. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.51.
Conclusion
In conclusion, Eton Pharmaceuticals Inc (ETON) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
